1. Market Research
  2. > Pharmaceutical Market Trends
  3. > Global Pharmaceutical Contract Manufacturing Market - Trends and Forecasts (2015 - 2020)

The Global Pharmaceutical Contract Manufacturing market was valued at USD 58 billion in 2014 and is projected to reach USD 84 billion in 2020, at a compound annual growth rate of 6.4% over the six year forecast period. Contract manufacturing refers to outsourcing of certain production activities to third party vendors. The pharmaceutical contract manufacturers are given the chemical formula of the drug to be manufactured by the pharmaceutical company. This market is witnessing high growth as the pharmaceutical companies are focusing more on R&D of the drugs instead of manufacturing the formulated drug to stay competitive in the market.

The companies in the upstream industry are undergoing restructuring so as to focus more on R&D, while stringent regulations on the pharmaceutical industry are compelling the companies to outsource the manufacturing of the drugs to contract manufacturers and focus on their core business processes.

Growing innovative drugs and increasing investments in R&D are some of the factors augmenting the growth of the market. However, some of the key impediments hindering the growth of the market are In-house packaging, capacity utilization issues affecting the profitability of CMOs and increasing lead time & logistics costs.

The market for global pharmaceutical contract manufacturing by type has been broadly segmented into active pharmaceutical ingredient (API) manufacturing, finished dosage formulation (FDF) development & manufacturing (sub-segmented further into solid dose formulation, liquid dose formulation & injectable dose formulation) and secondary market.

The market has also been geographically segmented into North America (United States and Canada), Europe (United Kingdom, Germany, France, Italy and Others), Asia-Pacific (China, India, Japan, Australia and Others), Latin America (Brazil, Mexico, Argentina and Others) and Middle East and Africa (United Arab Emirates, Saudi Arabia, South Africa, Nigeria and Others).

By dose formulation type, solid dose formulation constituted more than 40% of the overall pharmaceutical contract manufacturing market in 2014, attributing to lower cost of manufacturing, patent compliance and ease of maintenance. The segment is expected to grow at a CAGR of 3.66% over the forecast period, while injectable dose segment, will register highest CAGR of 12.37% over the next five years.

In 2014, the U.S. was the major market for pharmaceutical contract manufacturing, while India is estimated to be the fastest growing market owing to its cost competitiveness and quality manufacturing capabilities. Pharmaceutical companies are opting for less number of vendors to take volume advantage and at the same time, reduce logistics costs. They are increasingly relying on contract manufacturing, research, and packaging services to fulfill their basic needs and specialized competencies. The companies are striving to minimize costs and reduce the product development time, while at the same time being productive and efficient.

Huge demand for next-generation biological therapies has opened gateway of opportunities for the vendors/manufacturers across the globe. Some of the major companies mentioned in the report are Famar, Recipharm, Jubilant, Vetter, Pfizer Central Source, Aenova, Catalent and Haupt Pharma among others.

Key Deliverables in the Study

1. Market analysis for the global pharmaceutical contract manufacturing market, with region specific assessments and competition analysis on global and regional scales

2. Market definition along with the identification of key drivers and restraints

3. Identification of factors instrumental in changing the market scenarios, rising prospective opportunities, and identification of key companies that can influence this market on a global and regional scale

4. Extensively researched competitive landscape section with profiles of major companies along with their market shares

5. Identification and analysis of the macro and micro factors that affect the global pharmaceutical contract manufacturing market on both global and regional scales

6. A comprehensive list of key market players along with the analysis of their current strategic interests and key financial information

7. A wide-ranging knowledge and insights about the major players in this industry and the key strategies adopted by them to sustain and grow in the studied market

8. Insights on the major countries/regions in which this industry is blooming and to also identify the regions that are still untapped

Table Of Contents

Global Pharmaceutical Contract Manufacturing Market - Trends and Forecasts (2015 - 2020)
1. Introduction

1.1 Research Methodology

1.2 Key Findings

2. Executive Summary

3. Market Dynamics

3.1 Market Overview

3.2 Industry Value Chain Analysis

3.3 Industry Attractiveness - Porter's 5 Force Analysis

3.3.1 Bargaining Power of Suppliers

3.3.2 Bargaining Power of Consumers

3.3.3 Threat from new entrants

3.3.4 Threat from substitute products

3.3.5 Competitive rivalry within the industry

3.4 Industry Policies

3.5 Market Drivers

3.5.1 Growing Innovative drugs

3.5.2 Increasing investments in RandD

3.6 Market Restraints

3.6.1 In-house packaging

3.6.2 Capacity Utilization Issues Affecting the Profitability of CMOs

3.6.3 Increasing Lead Time and Logistics Costs

3.7 Market Opportunities

3.7.1 Huge Demand for Next-Generation Biological Therapies

4. Pharmaceutical Contract Manufacturing Market Segmentation, Forecasts and Trends - by Type

4.1 Active Pharmaceutical Ingredient (API) Manufacturing

4.2 Finished Dosage Formulation (FDF) Development and Manufacturing

4.2.1 Solid Dose Formulation

4.2.2 Liquid Dose/Semi-Solid Formulation

4.2.3 Injectable Dose Formulation

4.3 Secondary Market

5. Pharmaceutical Contract Manufacturing Market Segmentation, Forecasts and Trends - by Region

5.1 North America

5.1.1 United States

5.1.2 Canada

5.2 Europe

5.2.1 United Kingdom

5.2.2 Germany

5.2.3 France

5.2.4 Italy

5.2.5 Others

5.3 Asia Pacific

5.3.1 China

5.3.2 India

5.3.3 Japan

5.3.4 Australia

5.3.5 Others

5.4 Latin America

5.4.1 Brazil

5.4.2 Mexico

5.4.3 Argentina

5.4.4 Others

5.5 Middle East and Africa

5.5.1 United Arab Emirates

5.5.2 Saudi Arabia

5.5.3 South Africa

5.5.4 Nigeria

5.5.5 Others

6. Global Vendor Market Share Analysis

6.1 Pharmaceutical CMO Vendor Market Share

6.2 API Outsourcing Vendor Market Share (Top 10 Market Players)

7. Competitive Intelligence - Company Profiles

7.1 Catalent

7.2 Recipharm

7.3 Jubilant

7.4 Patheon

7.5 Vetter

7.6 Boehringer Ingelheim

7.7 Pfizer CentreSource

7.8 Aenova (Haupt)

7.9 Famar

7.10 Baxter Bio Pharma Solutions

7.11 Lonza

7.12 Biomeva

7.13 Fareva

8. Investment Analysis

8.1 Recent Mergers and Acquisitions

8.2 Investment Scenario and Opportunities

9. Future of Pharmaceutical Contract Manufacturing Market

Speak With Analy

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Prostate Cancer Pricing, Reimbursement, and Access

Prostate Cancer Pricing, Reimbursement, and Access

  • $ 7500
  • Industry report
  • July 2016
  • by Datamonitor Healthcare

Novel antiandrogens will need to present risk-sharing agreements in EU markets, while discussing contracting with US payers to ensure a competitive advantage. Vaccines suffer from inconclusive response ...

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

Global Pharmaceutical Contract Manufacturing Organization (CMO) Market

  • $ 7000
  • Industry report
  • August 2016
  • by Frost & Sullivan

Emerging Business Models Drive Transformation The key objective of this research is to provide in-depth knowledge of the major global pharmaceutical CMO market segments—active pharmaceutical ingredients ...

IMS World Review Executive™ 2016

IMS World Review Executive™ 2016

  • $ 6860
  • Industry report
  • July 2016
  • by IMS Health

IMS World Review ExecutiveTM 2016 provides essential insights into worldwide sales of the pharmaceutical market, interlocking market trends and sales analysis from 2011 to 2015, including the breakdown ...


Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.